Nightingale Health, the Finnish medtech which bills itself as “Europe’s answer to Theranos,” has received undisclosed investments from two Japanese giants, Mitsui & Co and Kirin Holdings Company. The new partnerships will introduce the pioneering blood test to the Japanese market as a consumer-facing wellness product called “My Nightingale.” The startup has also opened a new funding round to fuel further international expansion.
With its technology, Nightingale aims to shift the global medical paradigm from treatment to prevention, a system it refers to as “health-creation.” Over the past 5 years, Nightingale’s blood-testing technology has been used to publish more than 200 peer-reviewed scientific articles in the world’s leading biomedical journals.
“Our blood-test has been used by global leaders in medical science for years. Several scientific flagship studies have validated that Nightingale’s blood-test offers unprecedented insights into health and chronic diseases,” said CEO Teemu Suna. ”We think that people should have direct access to preventative next-generation health technologies – this is why our mission at Nightingale is to make our blood-test conveniently available globally to benefit everyone’s health.”
To achieve that goal, the medtech is raising more money; a private placement round of €50-80 million is currently open.
“We are honoured to have strong strategic partners in Japan and the US, who are not only investors in Nightingale but also business partners who are helping us take our technology to major markets. To make this launch as big as it deserves to be, we are raising – with the help of Carnegie – €50-80 million in a new round of funding,” said Suna.
He continued: “Launching the consumer service and starting the international roll-out of Nightingale’s technology is only the first step in our journey. In the coming years, we aim to expand rapidly and make Nightingale’s technology available all over the world, both to grow our business and help everyone live a healthier life.”